首页> 外文期刊>Integrative medicine insights >Effect of Kampo Medicine on Pain and Range of Motion of Osteoarthritis of the Hip Accompanied by Acetabular Dysplasia: Case Report and Literature Review
【24h】

Effect of Kampo Medicine on Pain and Range of Motion of Osteoarthritis of the Hip Accompanied by Acetabular Dysplasia: Case Report and Literature Review

机译:汉方药对髋臼异型增生伴髋关节疼痛和运动性骨关节炎的影响:病例报告及文献复习

获取原文
       

摘要

We report a 52-year-old female with end-stage osteoarthritis of the hip accompanied by acetabular dysplasia in whom quality of life (QOL) was improved by Kampo treatment. When she was 42 years old, she developed pain in the left hip joint, and early-stage OA of the hip was diagnosed by hip joint x-ray. Therefore, she took NSAIDs, and received conservative therapies such as diet and muscle training. However, pain in the hip joint increased and her activity of daily life (ADL) decreased at the age of 50, although she continued to receive the conservative therapies. At the age of 52, she consulted our department requesting Japanese Oriental (Kampo) Medicine. Kampo formulae; Keishikaryojutsubuto (12Tab/day: Kuracie Co. Ltd. Japan), and Boiougito (7.5 g/day: Kuracie Co. Ltd. Japan), were administered. Treatment for 3 months resulted in a decrease in the left hip joint pain using visual analogue scale (VAS) and improvement of her ADL. One year later, her joint symptoms have not increased, and both the Harris hip score and the clinical evaluation criteria of osteoarthritis of the hip have improved. The course of this disease varies depending on the lifestyle of the patient, and Kampo formulations may offer safe, potent supplemental treatment.
机译:我们报告了一名52岁女性,患有髋关节终末期骨关节炎并伴有髋臼发育不良,其中通过Kampo治疗改善了生活质量(QOL)。当她42岁时,她的左髋关节出现疼痛,并通过髋关节X线检查诊断出髋关节的早期OA。因此,她服用了非甾体抗炎药,并接受了饮食和肌肉训练等保守疗法。然而,尽管她继续接受保守疗法,但在50岁时,髋关节疼痛加剧,日常生活活动能力(ADL)下降。在52岁时,她咨询了我们的部门,要求使用日本东方(Kampo)医学。汉方配方;施用了Keishikaryojutsubuto(12Tab /天:日本Kuracie Co.Ltd。)和Boiougito(7.5g /天:Kuracie Co.Ltd.Japan)。使用视觉模拟量表(VAS)治疗3个月可减轻左髋关节疼痛并改善其ADL。一年后,她的关节症状没有增加,Harris髋关节评分和髋骨关节炎的临床评估标准均得到改善。此病的病程因患者的生活方式而异,Kampo制剂可提供安全有效的补充治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号